Analyst Research Roundup: Teva Pharmaceutical Industries Limited (TEVA), Molson Coors Brewing Company (TAP)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) tinted gains of +0.64% (+0.1 points) to US$15.68. The volume of 8.78 Million shares climbed up over an trading activity of 10.18 Million shares. EPS ratio determined by looking at last 12 month figures is -2.23. Over the same time span, the stock marked US$25.96 as its best level and the lowest price reached was US$14.59. The corporation has a market cap of US$17.73 Billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s earnings per share has been growing at a -28.5 percent rate over the past 5 year when average revenue increase was noted as -1.5 percent. The return on equity ratio or ROE stands at -16.6 percent while most common profitability ratio return on investment (ROI) was -3.2 percent. The company’s institutional ownership is monitored at 64.3 percent. The company’s net profit margin has achieved the current level of -12.7 percent and possesses 44 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 17 think it is Hold. Recently, analysts have updated the overall rating to 2.75. 2 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.

Molson Coors Brewing Company (NYSE:TAP) is worth US$13.26 Billion and has recently risen 0.64% to US$59.65. The latest exchange of 1.97 Million shares is above its average trading activity of 1.8 Million shares. The day began at US$59.69 but the price moved to US$59.44 at one point during the trading and finally capitulating to a session high of US$60.23. The stock tapped a 52-week high of US$76.45 while the mean 12-month price target for the shares is US$68.47.

Currently, the stock carries a price to earnings ratio of 11.57, a price to book ratio of 0.96, and a price to sales ratio of 1.23. For the past 5 years, the company’s revenue has grown 20.7%, while the company’s earnings per share has grown 10.9%. With an institutional ownership near 86.7%, it carries an earnings per share ratio of 5.16.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 8 analysts recommended Holding these shares while 1 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.